
SION Stock Forecast & Price Target
SION Analyst Ratings
Bulls say
Sionna Therapeutics is a promising biopharmaceutical company with a strong cash position and promising pipeline. The completion of patient enrollment for the Phase IIa PreciSION study in summer 2026 and potential positive results from this study, as well as the ongoing Phase I dual combo study, could greatly benefit the company and the CF community. With positive feedback from experts and plans for its own combination treatment, Sionna has the potential to revolutionize CF treatment and improve the lives of patients.
Bears say
Sionna Therapeutics is a clinical-stage biopharmaceutical company with a negative outlook, as there are concerns about the predictiveness of their preclinical data and the potential impact of subtle differences between their CFHBE work and that of their competitor, VRTX. Additionally, their stock target price has been raised to $55 from $44, yet their dual NBD1 combination revenues are only risk-adjusted at 40%. While SION has potential, its success is dependent on their ability to stabilize NBD1, which has historically been a difficult target to achieve with small molecule drugs.
This aggregate rating is based on analysts' research of Sionna Therapeutics Inc and is not a guaranteed prediction by Public.com or investment advice.
SION Analyst Forecast & Price Prediction
Start investing in SION
Order type
Buy in
Order amount
Est. shares
0 shares